FTC Claims Against PE Firm Put to Sleep

On May 13, the United States District Court for the Southern District of Texas ruled against the Federal Trade Commission’s antitrust claims against private equity firm Welsh Carson Anderson & Stowe. The FTC had targeted the firm for its role in forming U.S. Anesthesia Partners, Inc. and consolidating the Texas hospital anesthesia market. This ruling has significant implications for the FTC's strategy against private equity roll-ups in healthcare and sets a new precedent for future antitrust cases.

Read the full article.

About the authors:
Ian Dickinson
Lee K. Van Voorhis

Transcript

Welcome to womble perspectives, where we explore a wide range of topics, from the latest legal updates to industry trends to the business of law. Our team of lawyers, professionals and occasional outside guests will take you through the most pressing issues facing businesses today and provide practical and actionable advice to help you navigate the ever changing legal landscape. 

With a focus on innovation, collaboration and client service, we are committed to delivering exceptional value to our clients and to the communities we serve. And now our latest episode.

On May 13, the United States District Court for the Southern District of Texas ruled against the Federal Trade Commission’s antitrust claims against private equity firm Welsh Carson Anderson & Stowe. The FTC had targeted the firm for its role in forming U.S. Anesthesia Partners, Inc. and consolidating the Texas hospital anesthesia market. This ruling has significant implications for the FTC's strategy against private equity roll-ups in healthcare and sets a new precedent for future antitrust cases.

Private equity roll-ups involve the acquisition and consolidation of smaller companies within a market to create a larger entity. While this can lead to increased efficiency and market reach, it can also reduce competition and lead to higher prices. The FTC has been vigilant in scrutinizing these practices, particularly in the healthcare sector where market consolidation can directly impact consumer costs and access to services.

In September 2023, the FTC filed a complaint against Welsh Carson Anderson & Stowe and U.S. Anesthesia Partners, Inc. The FTC alleged that the firm's creation and consolidation strategy for U.S. Anesthesia Partners had led to reduced competition and increased prices for patients and employers in Texas. These allegations were based on Section 13b of the FTC Act, which allows the FTC to seek injunctive relief when a business is violating or about to violate any law within the FTC’s enforcement authority.

By the time of the FTC's complaint, U.S. Anesthesia Partners controlled approximately 60% of all hospital-based anesthesia services in the state. This dominance in the market was the cornerstone of the FTC’s allegations against Welsh Carson Anderson & Stowe.

To support its case, the FTC needed to demonstrate that the entities were engaged in ongoing or imminent violations of antitrust laws. 

The court ultimately dismissed the FTC’s claims against Welsh Carson Anderson & Stowe, citing several key reasons. They determined that the firm's 23% equity stake in U.S. Anesthesia Partners, which included just two out of 14 board seats, did not constitute sufficient control to hold the company liable for ongoing antitrust violations. Additionally, the firm's limited involvement in U.S. Anesthesia Partners' day-to-day operations further insulated them from liability. Furthermore, the FTC's allegations lacked concrete evidence that Welsh Carson Anderson & Stowe was currently violating or about to violate antitrust laws.

While Welsh Carson Anderson & Stowe was able to escape liability, U.S. Anesthesia Partners' motion to dismiss was denied. The court found plausible evidence that it continued to operate and maintain acquired anesthesia groups, which could constitute ongoing violations of antitrust law, meaning that the case against U.S. Anesthesia Partners will proceed.

The dismissal of claims against Welsh Carson Anderson & Stowe represents a setback for the FTC's strategy of targeting private equity roll-ups in the healthcare sector. This ruling suggests that minority investors in such roll-ups may be insulated from antitrust liability, provided they do not exert significant control over the consolidated entity.

However, entities that own or control ongoing consolidation efforts, like U.S. Anesthesia Partners, remain at risk of exposure to antitrust actions.

The FTC may choose to appeal the court’s decision, which could lead to further legal scrutiny and potentially change the current interpretation of Section 13b. An appeal could also provide additional clarity on the extent of liability for minority investors in private equity roll-ups.

Despite this ruling, the FTC and the Department of Justice are likely to continue their focus on healthcare market consolidations. Industry stakeholders should remain vigilant and ensure compliance with competition laws to avoid potential legal challenges.

Thank you for listening to womble perspectives. If you want to learn more about the topics discussed in this episode, please visit the show notes where you can find links to related resources mentioned today. 

The show notes also have more information about our attorneys who provided today's insights, including ways to reach out to them. Don't forget to subscribe via your podcast player of choice so that you never miss an episode. Thank you again for listening.